Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.47 |
| ▸ | CTSS | P25774 | 6/20 | 0.47 |
| ▸ | CTSK | P43235 | 6/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.39 |
| ▸ | FAP | Q12884 | 8/20 | 0.38 |
| ▸ | PREP | P48147 | 8/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CTSV | O60911 | 1/20 | 0.36 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4762204 | 0.97 | CTSK (0.45) | CTSLCTSSCTSKCTSBFAP | |
| SCHEMBL4766629 | 0.86 | CTSK (0.46) | CTSLCTSSCTSKCTSBCCR1 | |
| SCHEMBL4823843 | 0.86 | TAS1R3 (0.49) | CTSLCTSSCTSKCTSBCCR1 | |
| SCHEMBL4763062 | 0.86 | GRN (0.47) | CTSLCTSSCTSKCTSBCCR1 | |
| SCHEMBL4765600 | 0.86 | CTSK (0.54) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL4768321 | 0.84 | CCR1 (0.42) | CTSLCTSSCTSKCTSBCCR1 | |
| SCHEMBL4765494 | 0.84 | CTSK (0.40) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL4765041 | 0.83 | CTSK (0.43) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL7534924 | 0.83 | CTSK (0.42) | CTSLCTSSCTSKCTSBFAP | |
| SCHEMBL4770472 | 0.83 | CTSK (0.42) | CTSLCTSSCTSKCTSBCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320370-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1320370-A1 | METHOD OF TREATMENT | SmithKline Beecham Corporation (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002017924-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-03-07 | — | — | WO | disclosed |